Dante Ravetti

Array ( [id] => 17505454 [patent_doc_number] => 20220098556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => SEED CULTURE PROCESS FOR AAV PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/425618 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272219 [patent_doc_number] => 12441989 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Serum-free medium for avian vaccine production and uses thereof [patent_app_type] => utility [patent_app_number] => 17/414759 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 999 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17414759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18266106 [patent_doc_number] => 20230087348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => USE OF HLA-A*11:01-RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES FOR IDENTIFYING HBV-SPECIFIC CD8+ T CELLS [patent_app_type] => utility [patent_app_number] => 17/421816 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520743 [patent_doc_number] => 20220106592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => DUX4 RNA Silencing Using RNA Targeting CRISPR-CAS13b [patent_app_type] => utility [patent_app_number] => 17/419171 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426903 [patent_doc_number] => 20220054611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES AND RNA IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/413853 [patent_app_country] => US [patent_app_date] => 2019-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441904 [patent_doc_number] => 20220062409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/413203 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426910 [patent_doc_number] => 20220054618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE [patent_app_type] => utility [patent_app_number] => 17/413228 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18272540 [patent_doc_number] => 20230093782 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-03-23 [patent_title] => SUBUNIT VACCINE CONSTRUCTS FOR FLAVIVIRUSES [patent_app_type] => utility [patent_app_number] => 17/312534 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18272540 [patent_doc_number] => 20230093782 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-03-23 [patent_title] => SUBUNIT VACCINE CONSTRUCTS FOR FLAVIVIRUSES [patent_app_type] => utility [patent_app_number] => 17/312534 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17445352 [patent_doc_number] => 20220065857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => HIV SEROSIGNATURES FOR CROSS-SECTIONAL INCIDENCE ESTIMATION [patent_app_type] => utility [patent_app_number] => 17/312916 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961593 [patent_doc_number] => 12331077 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Stabilized pre-fusion RSV F proteins [patent_app_type] => utility [patent_app_number] => 17/293364 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 11 [patent_no_of_words] => 7370 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731265 [patent_doc_number] => 12209256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction [patent_app_type] => utility [patent_app_number] => 17/289336 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 14475 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20578484 [patent_doc_number] => 12570726 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Anti-HIV antibody and method for producing same [patent_app_type] => utility [patent_app_number] => 17/290054 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 5472 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492653 [patent_doc_number] => 12534516 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Anti-HIV antibodies [patent_app_type] => utility [patent_app_number] => 17/287188 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 13 [patent_no_of_words] => 63696 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451934 [patent_doc_number] => 20230193213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/419792 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299935 [patent_doc_number] => 20210395774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => NOVEL VIRUS VECTOR AND METHODS FOR PRODUCING AND USING SAME [patent_app_type] => utility [patent_app_number] => 17/279330 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480679 [patent_doc_number] => 20220088183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATES AN ANTITUMOR IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/271403 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701730 [patent_doc_number] => 12195745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Compositions and methods for modulating transduction efficiency of adeno-associated viruses [patent_app_type] => utility [patent_app_number] => 17/269955 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 12418 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17688250 [patent_doc_number] => 20220195542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => USE OF PRIMER PROBE COMBINATION AND KIT THEREOF IN HBV DETECTION [patent_app_type] => utility [patent_app_number] => 17/599578 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17300922 [patent_doc_number] => 20210396761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHODS FOR SCREENING AND IDENTIFYING AGENTS THAT INHIBIT OR MODULATE THE NUCLEAR EGRESS COMPLEX OF HERPESVIRUSES [patent_app_type] => utility [patent_app_number] => 17/261501 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261501 [rel_patent_id] =>[rel_patent_doc_number] =>)